What is circulating factor disease and how is it currently explained?

Circulating factor disease Nephrotic syndrome Steroid sensitive nephrotic syndrome Steroid-resistant nephrotic syndrome Transplant recurrence

Journal

Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728

Informations de publication

Date de publication:
11 2023
Historique:
received: 13 01 2023
accepted: 20 02 2023
revised: 15 02 2023
medline: 22 9 2023
pubmed: 24 3 2023
entrez: 23 3 2023
Statut: ppublish

Résumé

Nephrotic syndrome (NS) consists of the clinical triad of hypoalbuminaemia, high levels of proteinuria and oedema, and describes a heterogeneous group of disease processes with different underlying drivers. The existence of circulating factor disease (CFD) as a driver of NS has been epitomised by a subset of patients who exhibit disease recurrence after transplantation, alongside laboratory work. Several circulating factors have been proposed and studied, broadly grouped into protease components such as soluble urokinase-type plasminogen activator (suPAR), hemopexin (Hx) and calcium/calmodulin-serine protease kinase (CASK), and other circulating proteases, and immune components such as TNF-α, CD40 and cardiotrophin-like cytokine-1 (CLC-1). While currently there is no definitive way of assessing risk of CFD pre-transplantation, promising work is emerging through the study of 'multi-omic' bioinformatic data from large national cohorts and biobanks.

Identifiants

pubmed: 36952039
doi: 10.1007/s00467-023-05928-8
pii: 10.1007/s00467-023-05928-8
pmc: PMC10514121
doi:

Substances chimiques

Receptors, Urokinase Plasminogen Activator 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3513-3518

Subventions

Organisme : Medical Research Council
ID : MR/W000105/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R003017/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P024297/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R013942/1
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

J Am Soc Nephrol. 2014 Jun;25(6):1342-8
pubmed: 24511128
Nephron. 2018;138(1):71-87
pubmed: 28965116
Clin J Am Soc Nephrol. 2010 Nov;5(11):2115-21
pubmed: 20966123
Pediatr Nephrol. 2018 Oct;33(10):1773-1780
pubmed: 29982878
Sci Transl Med. 2014 Oct 1;6(256):256ra136
pubmed: 25273097
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2970-E2979
pubmed: 29531073
J Am Soc Nephrol. 2008 Nov;19(11):2140-9
pubmed: 18753258
Transl Res. 2008 Jun;151(6):288-92
pubmed: 18514139
BMC Nephrol. 2016 Jul 29;17(1):104
pubmed: 27473582
Lancet. 1974 Sep 7;2(7880):556-60
pubmed: 4140273
Pediatr Nephrol. 2023 Jan;38(1):145-159
pubmed: 35507150
N Engl J Med. 2013 Dec 19;369(25):2416-23
pubmed: 24206430
Int J Epidemiol. 2021 Jan 23;49(6):2058-2064
pubmed: 31298274
Clin Nephrol. 2020 Sep;94(3):117-126
pubmed: 32589135
N Engl J Med. 2001 Feb 1;344(5):386-7
pubmed: 11195803
J Immunol Res. 2015;2015:714964
pubmed: 26146641
Pediatr Nephrol. 2005 Oct;20(10):1410-5
pubmed: 16079987
Sci Rep. 2022 May 6;12(1):7433
pubmed: 35523803
Nephron. 2018;139(4):334-341
pubmed: 29909410
Kidney Int Rep. 2019 Sep 19;5(1):66-80
pubmed: 31922062
N Engl J Med. 2012 Apr 26;366(17):1648-9
pubmed: 22533598
Kidney Int. 2017 Apr;91(4):937-947
pubmed: 28117080
Arthritis Rheumatol. 2021 Feb;73(2):212-222
pubmed: 32909363
PLoS One. 2019 Jul 29;14(7):e0219353
pubmed: 31356645
Pediatr Nephrol. 2012 Dec;27(12):2217-26
pubmed: 22538781
J Pathol. 2013 Apr;229(5):660-71
pubmed: 23436459
J Am Soc Nephrol. 2005 Mar;16(3):629-37
pubmed: 15659563
Pediatr Nephrol. 2013 Nov;28(11):2131-5
pubmed: 23793883
Transplantation. 2002 Feb 15;73(3):394-403
pubmed: 11884936
J Clin Invest. 1999 Dec;104(11):1559-66
pubmed: 10587519
Biomolecules. 2020 Mar 30;10(4):
pubmed: 32235589
Clin Cancer Res. 2018 Mar 15;24(6):1248-1259
pubmed: 28982688
Kidney Int. 2000 Apr;57(4):1512-20
pubmed: 10760087
Front Bioinform. 2021 Sep 22;1:746712
pubmed: 36303798
J Am Soc Nephrol. 2022 Jan;33(1):238-252
pubmed: 34732507
Pediatr Nephrol. 2021 Nov;36(11):3757-3769
pubmed: 34031708
Kidney Int. 2023 Aug;104(2):265-278
pubmed: 36940798
Kidney Int. 2004 Jul;66(1):133-43
pubmed: 15200420
Brief Bioinform. 2022 Sep 20;23(5):
pubmed: 35947992
N Engl J Med. 1994 Jan 6;330(1):7-14
pubmed: 8259160
Pediatr Nephrol. 2003 Jun;18(6):516-20
pubmed: 12707837
Kidney Int. 2013 Aug;84(2):366-72
pubmed: 23447064
J Am Soc Nephrol. 2016 Aug;27(8):2520-7
pubmed: 26701979
Clin Sci (Lond). 1989 Jul;77(1):43-8
pubmed: 2758761
Kidney Int. 2005 Aug;68(2):603-10
pubmed: 16014037
Pediatr Nephrol. 2018 Nov;33(11):2027-2035
pubmed: 29022104
Am J Physiol Renal Physiol. 2019 Oct 1;317(4):F913-F921
pubmed: 31339775
J Immunol Res. 2016;2016:2068691
pubmed: 27504461
EBioMedicine. 2022 Oct;84:104276
pubmed: 36179553
Nat Med. 2011 Jul 31;17(8):952-60
pubmed: 21804539
J Am Soc Nephrol. 1992 Jun;2(12 Suppl):S258-63
pubmed: 1498285

Auteurs

Samantha Hayward (S)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Samantha.Hayward@nhs.net.
MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Samantha.Hayward@nhs.net.

Kevon Parmesar (K)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Moin A Saleem (MA)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH